Vertex Pharmaceuticals (WBO:VRTX) Long-Term Capital Lease Obligation : €665 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Long-Term Capital Lease Obligation?

Vertex Pharmaceuticals's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €665 Mil.

Vertex Pharmaceuticals's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 (€708 Mil) to Sep. 2023 (€698 Mil) and declined from Sep. 2023 (€698 Mil) to Dec. 2023 (€665 Mil).

Vertex Pharmaceuticals's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€785 Mil) to Dec. 2022 (€765 Mil) and declined from Dec. 2022 (€765 Mil) to Dec. 2023 (€665 Mil).

Vertex Pharmaceuticals Long-Term Capital Lease Obligation Historical Data

The historical data trend for Vertex Pharmaceuticals's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Long-Term Capital Lease Obligation Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

560.58

731.17

785.17

764.92

664.55

Vertex Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															764.92	737.11	708.50	697.78	664.55

Vertex Pharmaceuticals (WBO:VRTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Vertex Pharmaceuticals Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (WBO:VRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.